加载中...
广告
发布时间 | 所属地区 | 所属机构 | 语言 |
---|---|---|---|
2024年06月19日 | -- | -- | 英语 (English) 中文 |
Published date: 19 June 2024 Open opportunity - This means that the contract is currently active, and the buying department is looking for potential suppliers to fulfil the contract.
Watch this notice
Print this notice
Closing: 31 July 2024, 12pm
Contract summaryIndustryMedical equipments, pharmaceuticals and personal care products - 33000000 Health services - 85100000 Pharmacy services - 85149000 Location of contractLS1 4AP Value of contract£1 Procurement referenceCF-2418700D0O000000rwimUAA Published date19 June 2024 Closing date31 July 2024 Closing time12pm Contract start date15 October 2024 Contract end date30 June 2026 Contract typeService contract Procedure typeOpen procedure (above threshold)
What is an open procedure (above threshold)?
Any interested supplier may submit a tender in response to an opportunity notice. This procedure can be used for procurements above the relevant contract value threshold. Contract is suitable for SMEs?Yes Contract is suitable for VCSEs?No DescriptionNHS England requires a supplier to apply for a major (type II) MHRA Marketing Authorisation variation for spironolactone. The variation is to add a new indication to the current licence (marketing authorisation) for treating acne in women. The Successful Supplier would need to prepare a dossier for the MHRA including a Risk Management Plan, apply for the licence variation, and if granted update their licence, Summary of Product Characteristics and patient information leaflet with the new indication and related data. More information
How to applyFollow the instructions given in the description or the more information section. About the buyerContact nameLeigh Parker AddressNHS England Is there anything wrong with this page? |
上一篇:
CA14283 - United Colleges Group - ESOL with Maths provision to unemployed learners下一篇:
Energy NTSN authorisation support猜你喜欢
加载中...
广告